The most significant insider buy on today's list comes via two separate Form 4 filings by the president and the CEO of The Charles Schwab Corporation $SCHW.
They reported purchases for a combined amount of $2.2 million.
Here’s The Hot Corner, with data from July 19, 2024:
Director John W. Childs reported the acquisition of 28,400 shares in Biohaven Pharmaceutical Holding Company Ltd $BHVN.
BHVN came public in September 2022 and ripped higher with authority. However, price has retraced some gains since it peaked in March, successfully retesting a critical polarity level.
The line in the sand lies at 27.
If we're above this level, the risk is still to the upside.
Stay tuned. We'll be back on Tuesday with more insider activity.
